Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

832P - CLOMB: A validated scoring model to predict the relapse in the central nervous system of pediatric acute B-cell lymphoblastic leukemia

Date

14 Sep 2024

Session

Poster session 09

Presenters

Jiacheng Li

Citation

Annals of Oncology (2024) 35 (suppl_2): S596-S612. 10.1016/annonc/annonc1593

Authors

J. Li1, Y. Tao1, J. Yu2, H. You1

Author affiliations

  • 1 Laboratory For Excellence In Systems Biomedicine Of Pediatric Oncology, Children's Hospital of Chongqing Medical University, 400010 - Chongqing/CN
  • 2 Department Of Pediatric Hematology And Oncology, Children's Hospital of Chongqing Medical University, 400010 - Chongqing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 832P

Background

Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.

Methods

1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.

Results

The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.

Conclusions

The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Natural Science Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.